You are here

Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Narumi Himawari Clinic
Nagoya, Aichi, 458-0801 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatient status.

- A primary diagnosis of MDD based on the criteria in the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM- IV-TR), single or recurrent episode,
without psychotic features.

- Depressive symptoms for at least 90 days in single episode and for at least 28 days in
recurrent episode before the screening visit.

- A MADRS total score ≥26 at the screening and baseline visits. And change of MADRS
total score at baseline is not over 25% from the screening visit.

- A QIDS16-J-SR score ≥16 at the screening and baseline visits.

- A score ≥4 on the Clinical Global Impressions Scale-Severity (CGI-S) at the screening
and baseline visits.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who concurrently have Axis II personality disorder or mental retardation
according to DSM-IV diagnostic criteria.

- Subjects who meet DSM-IV criteria for current or past history of Schizophrenia,
Paranoid Disorders, or any other Psychotic Disorders.

- Subjects who meet DSM-IV criteria for current or past history of Dementia.

- Subjects who meet DSM-IV criteria for current or past history of bipolar disorder,
Posttraumatic Stress Disorder (PTSD) or Obsessive Compulsive Disorder (OCD).

- Subjects who meet DSM-IV criteria for current (within 12 months before the screening
visit) generalized anxiety disorder, panic disorder, or social anxiety disorder
considered by the investigator to be primary (causing a higher degree of distress or
impairment than MDD).

- Subjects with a first degree relative with bipolar disorder.

- Subjects who are actively suicidal.

- History of non-responsive to 2 antidepressant treatment (at least 6-week usage for
each) for the past or current episodes.

- History of Electroconvulsive therapy (ECT) at any time in the past.

- History of chronic treatment with benzodiazepines for longer than 6 months before the
screening visit (Excluding subjects who have taken PRN benzodiazepine use, times/week).

- Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled
hypertension), ophthalmologic, neurologic, or any other medical condition that in the
investigator's judgment, will substantially increase the risk associated with the
subject's participation in and completion of, the study.

- Known presence of raised intraocular pressure or history or presence of narrow angle
glaucoma.

- Myocardial infarction within 180 days of the screening visit.

- Clinically important abnormalities, as determined by the investigator, on screening
physical examination, electrocardiogram (ECG) or laboratory tests.

- Use of prohibited treatments

NCT01441440
Pfizer
Completed
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now